|
【结 构 式】 
|
【分子编号】44878 【品名】ethyl 2-[4-(1lambda(3)-dibromanylcarbonyl)phenoxy]acetate 【CA登记号】 |
【 分 子 式 】C11H12Br2O4 【 分 子 量 】368.02188 【元素组成】C 35.9% H 3.29% Br 43.42% O 17.39% |
合成路线1
该中间体在本合成路线中的序号：(IV)Synthesis of intermediate (VI): Treatment of 2-oxopiperazine (I) with di-t-butyl dicarbonate (II) and Et3N in DMF affords 1-t-butoxycarbonyl-3-oxopiperazine (III), which is then condensed with bromo derivative (IV) by means of NaH in THF, providing ethyl phenoxyacetate derivative (V). Treatment of (V) with HCl/EtOAc allows removal of the t-butyloxycarbonyl group, yielding intermediate (VI). Alternatively, intermediate (VI) can be obtained by first formylation of (I) with formic acid and acetic anhydride (Ac2O) in CH2Cl2 to afford derivative (VII), followed by condensation of (VII) with (IV) to give (VIII) by means of NaH in DMF/THF and deformylation by treatment with HCl/EtOAc to afford (VI).
| 【1】 Ohuchi, S.; Suzuki, H.; Ando, T.; Katano, K.; Imai, T.; Kobayashi, K.; Ota, K.; Aizawa, K.; Miura, T. (Meiji Seika Kaisha, Ltd.); Nitrogen-containing heterocyclic cpds. having antiplatelet aggregation effect and medicinal use thereof. EP 1070712; WO 9952894 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 44876 | 2-piperazinone | C4H8N2O | 详情 | 详情 | |
| (II) | 11147 | di(tert-butyl) carbonate | C9H18O3 | 详情 | 详情 | |
| (III) | 44877 | tert-butyl 3-oxo-1-piperazinecarboxylate | C9H16N2O3 | 详情 | 详情 | |
| (IV) | 44878 | ethyl 2-[4-(1lambda(3)-dibromanylcarbonyl)phenoxy]acetate | C11H12Br2O4 | 详情 | 详情 | |
| (V) | 44879 | tert-butyl 4-[2-[4-(2-ethoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-3-oxo-1-piperazinecarboxylate | C21H28N2O7 | 详情 | 详情 | |
| (VI) | 44880 | ethyl 2-[4-[2-(2-oxo-1-piperazinyl)acetyl]phenoxy]acetate | C16H20N2O5 | 详情 | 详情 | |
| (VII) | 44881 | 3-oxo-1-piperazinecarbaldehyde | C5H8N2O2 | 详情 | 详情 | |
| (VIII) | 44882 | ethyl 2-[4-[2-(4-formyl-2-oxo-1-piperazinyl)acetyl]phenoxy]acetate | C17H20N2O6 | 详情 | 详情 |
合成路线2
该中间体在本合成路线中的序号：(IV)Reductive condensation of 2-oxopiperazine (I) with 4-oxopiperidine-1-carboxylic acid t-butyl ester (XIV) in the presence of sodium cyanoborohydride (NaBH3CN) in MeOH/EtOH-HCl yields derivative (XV), which is then coupled to bromo derivative (IV) by means of sodium in refluxing toluene to give compound (XVI). Deprotection of (XVI) by treatment with TFA and anisole provides piperidine derivative (XVII), which is then treated with chloromethyl chloroformate (X) and proton sponge in CH2Cl2 to furnish derivative (XVIII). Finally, (XVIII) is coupled to pivalic acid (XII) by means of K2CO3 in DMF and converted into the corresponding hydrochloride salt by treatment with HCl-EtOH in EtOAc.
| 【1】 Katano, K.; Ohuchi, S.; Miura, T.; Shitara, E.; Shimizu, M.; Yaegashi, K.; Ohkura, N.; Isomura, Y.; Iida, H.; Ishikawa, M.; Asai, K.; Hatsushiba, E. (Meiji Seika Kaisha, Ltd.); Novel cpd. having platelet aggregation inhibitor effect. EP 0721941; US 5814636; WO 9602503 . |
| 【2】 Ohuchi, S.; Suzuki, H.; Ando, T.; Katano, K.; Imai, T.; Kobayashi, K.; Ota, K.; Aizawa, K.; Miura, T. (Meiji Seika Kaisha, Ltd.); Nitrogen-containing heterocyclic cpds. having antiplatelet aggregation effect and medicinal use thereof. EP 1070712; WO 9952894 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 44876 | 2-piperazinone | C4H8N2O | 详情 | 详情 | |
| (IV) | 44878 | ethyl 2-[4-(1lambda(3)-dibromanylcarbonyl)phenoxy]acetate | C11H12Br2O4 | 详情 | 详情 | |
| (X) | 19249 | Chloromethyl chloroformate; Chloro[(chlorocarbonyl)oxy]methane | 22128-62-7 | C2H2Cl2O2 | 详情 | 详情 |
| (XII) | 44281 | pivalic acid | 75-98-9 | C5H10O2 | 详情 | 详情 |
| (XIV) | 44886 | tert-butyl 4-oxo-4lambda(5)-piperazine-1-carboxylate | C9H18N2O3 | 详情 | 详情 | |
| (XV) | 44887 | C13H24N4O3 | 详情 | 详情 | ||
| (XVI) | 44888 | C24H35BrN4O7 | 详情 | 详情 | ||
| (XVII) | 44889 | C20H28N4O5 | 详情 | 详情 | ||
| (XVIII) | 44890 | C22H29ClN4O7 | 详情 | 详情 |